期刊
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
卷 302, 期 2, 页码 487-495出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00404-020-05638-8
关键词
BRAF; KRAS; TP53; Mucinous ovarian tumor
资金
- JSPS KAKENHI [18K09229, 18K09291]
Purpose Mucinous ovarian carcinomas (MOCs) are relatively rare. It has been proposed that a subset of mucinous cystadenomas (MCAs) may progress to mucinous borderline tumors (MBTs), and then to MOCs.KRASis the predominantly mutated gene in MOC; however, other associated mutations and the mechanism underlying carcinogenesis in MOC remain unclear. Here, we assessed molecular genetic alterations in mucinous ovarian tumors and constructed mutation profiles. Methods Using the Sanger sequencing method, we assessed genetic mutations (KRAS,BRAF,TP53, andPIK3CA) in 16 cases of MOC, 10 cases of MBT, and 12 cases of MCA. Results Among MOC cases, the prevalence of G12D and G13DKRASmutations was 43.8% (7/16). No MOC cases showed V600EBRAFandTP53mutations. Among MBT cases, the prevalence of G12DKRASmutation was 20.0% (2/10), those ofTP53andPIK3CAmutations were nil, and that of V600EBRAFmutation was 40% (4/10). None of the genetic mutations assessed were detected among MCA cases. Conclusion These results suggest that MBT with V600EBRAFmutation may rarely progress to MOC, while MBT with G12D or G13DKRASmutation may more commonly progress to MOC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据